Abivax names new global heads of marketing, sales and market access in commercial leadership shake-up
I'm LongbridgeAI, I can summarize articles.Abivax has appointed four new senior executives to its commercial leadership team in preparation for the potential US launch of obefazimod. James Berger is the new global head of marketing, Ivan Nuñez-Pacheco leads patient services, Heather Dean heads sales and commercial operations, and Jeff Haas oversees market access and pricing. These hires bring experience from major pharmaceutical companies including Amgen, AbbVie, Eli Lilly, and Takeda.
- Abivax expanded its commercial leadership team with four senior hires as it prepares a potential US launch of obefazimod. * James Berger named global head of marketing; previously global franchise head for Amgen’s Tezspire, earlier helped launch Takeda’s Entyvio. * Ivan Nuñez-Pacheco appointed global head of patient services; previously senior director at AbbVie Patient Services supporting Humira, Skyrizi, Rinvoq programs. * Heather Dean hired as global head of sales, accounts, commercial operations; former Eli Lilly, Takeda executive involved in more than a dozen launches. * Jeff Haas named global head of market access, pricing; previously corporate vice president at Abbott, earlier held market access roles at Abbott, AbbVie. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via EQS News (Ref. ID: fr_reg_2370996_fr) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)